Gastrointestinal Cancer | Specialty

Dr. Janjigian on the FDA Approval of Nivolumab Plus Chemotherapy in Frontline Gastric Cancer

May 11th 2021

Yelena Y. Janjigian, MD, discusses the FDA approval of nivolumab plus chemotherapy in frontline gastric cancer.

Dr. Patel on Selecting Patients for Treatment With Atezolizumab/Bevacizumab in HCC

May 11th 2021

Monica A. Patel, MD, discusses factors that determine whether a patient with hepatocellular carcinoma is a good candidate to receive a combination of atezolizumab and bevacizumab.

FDA Grants Orphan Drug Designation to BOLD-100 for Gastric Cancer

May 11th 2021

The FDA has granted an orphan drug designation to the first-in-class ruthenium-based small molecule therapeutic BOLD-100 for the treatment of patients with gastric cancer.

Multidisciplinary Care Is Paramount as New Therapies Emerge in Metastatic Pancreatic Cancer

May 6th 2021

Although the standard-of-care treatment for patients with metastatic pancreatic cancer remains largely unchanged with multi-agent chemotherapy, the role for multidisciplinary care has expanded significantly in recent years.

The Future of Cancer Immunotherapy Lies in Combinational Approaches

May 6th 2021

Arsen Osipov, MD, discusses the potential for ongoing research with immunotherapeutic approaches in gastrointestinal malignancies, including CAR T-cell therapy, bispecific T-cell engagers, and vaccines.

Dr. Lee on Selecting a Treatment Approach for Neuroendocrine Tumors

May 6th 2021

Yoomi Lee, MD, discusses her process for selecting a treatment approach for patients with neuroendocrine tumors.

Dr. Uboha on Early Efficacy Data With Zanidatamab in HER2+ Upper GI Cancers

May 5th 2021

Nataliya V. Uboha, MD, PhD, discusses early efficacy data demonstrated with zanidatamab in HER2-expressing upper gastrointestinal cancers.

FDA Approves Pembrolizumab for HER2+ Gastric Cancer

May 5th 2021

The FDA has approved pembrolizumab for use in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction adenocarcinoma.

FDA Grants Priority Review to Ivosidenib in IDH1-Mutant Cholangiocarcinoma

May 5th 2021

The FDA has granted a priority review to the supplemental new drug application for ivosidenib tablets as a treatment option for patients with previously treated, IDH1-mutant cholangiocarcinoma.

Rolling Submission Completed for Surufatinib in Advanced Neuroendocrine Tumors

May 3rd 2021

The rolling submission of a new drug application to the FDA for surufatinib for the treatment of patients with pancreatic and non-pancreatic neuroendocrine tumors has been completed.